TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23043368
Drug: CNTO 5825
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 5825 (10 mg kg(‐1) i.v.) in healthy atopic subjects
Study: 21127156
Drug: Probiotic E.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic E. coli strain Nissle 1917 (Mutaflor), administered at a daily dose of 5×10(9)‐5×10(10) bacteria, twice daily.
Study: 18781073
Drug: Yacon syrup
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon syrup (20 g daily, equal to 6.4 g FOS)
Study: 16438769
Drug: Infero-nasal sub-Tenon's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infero-nasal sub-Tenon's injection of lidocaine 2% with hyaluronidase 15 IU mL‐1
Study: 16438769
Drug: Infero-temporal sub-Tenon's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infero-temporal sub-Tenon's injection of lidocaine 2% with hyaluronidase 15 IU mL‐1
Study: 12492739
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (proton pump inhibitor plus amoxicillin and clarithromycin for 1 week)
Study: 12492739
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor alone for 8 weeks
Study: 12492739
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (for ulcers of < 1.0 cm)
Study: 12492739
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor alone (for ulcers of < 1.0 cm)
Study: 12492739
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (for ulcers of 1.0 to < 1.5 cm)
Study: 12492739
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor alone (for ulcers of 1.0 to < 1.5 cm)
Study: 12492739
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (for ulcers of > or = 1.5 cm)
Study: 12492739
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor alone (for ulcers of > or = 1.5 cm)
Study: 10865302
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (75, 150, or 225 mg/d)
Study: 7902034
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg and 0.9 mg/kg
Study: 3030619
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (mean dose: 29 g)
Study: 3030619
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (mean dose: 33 g)
Study: 29574039
Drug: E39 peptide
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E39 peptide vaccine (500 μg or 1000 μg)
Study: 29574039
Drug: E39 followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E39 followed by E39' (500 μg or 1000 μg)
Study: 29574039
Drug: E39' followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: E39' followed by E39 (500 μg or 1000 μg)
Study: 11010060
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 0.5% ophthalmic solution, instilled four times daily for 6 weeks
Study: 11010060
Drug: Levocabastine 0.05%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine 0.05%, instilled four times daily for 6 weeks
Study: 11010060
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine vehicle, instilled four times daily for 6 weeks
Study: 8617884
Drug: Adenovirus vector
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus vector encoding cystic fibrosis transmembrane conductance regulator, administered to the nasal epithelium with five escalating doses of up to 10(10) infectious units.
Study: 8617884
Drug: Adenovirus vector
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus vector encoding cystic fibrosis transmembrane conductance regulator, administered to the nasal epithelium.
Study: 1306646
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immune globulin (HDivIG) therapy at 500 mg/kg for a 2-hour period
Study: 8499737
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment including phototherapy
Study: 1306646
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immune globulin (HDivIG) therapy
Study: 6378236
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (200 mg four times daily for six weeks)
Study: 25440807
Drug: Sevoflurane inhalation
Normalized name: Sevoflurane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane inhalation
Study: 29361285
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy (Simvastatin and Ezetimibe)
Study: 21043369
Drug: Intravaginal gel
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal gel (Prepidil)
Study: 16563861
Drug: Self-massage and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-massage and skin care using a cream containing aromatherapy oils
Study: 16563861
Drug: Self-massage and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-massage and skin care using a cream without aromatherapy oils
Study: 11688002
Drug: Methylprednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (30 mg/kg intravenously)
Study: 26718578
Drug: 10,400 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,400 IU cholecalciferol daily for 6 months
Study: 26718578
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU cholecalciferol daily for 6 months
Study: 17919763
Drug: Glimepiride 3mg
Normalized name: GLIMEPIRIDE 3MG TAB
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride 3mg (morning) and insulin glargine (bedtime) with dose titration
Study: 10392329
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg and 10 mg, diltiazem 200 mg and 300 mg, mibefradil 50 mg and 100 mg
Study: 10392329
Drug: Mibefradil (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (low dose)
Study: 10392329
Drug: Mibefradil (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil (high dose)
Study: 8888913
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron therapy for adolescents with s-ferritin < 12 micrograms l-1
Study: 1986667
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 micrograms twice daily)
Study: 3885387
Drug: Dextromethorphan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (20 mg)
Study: 3885387
Drug: Codeine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (20 mg)
Study: 20632489
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (Group A)
Study: 20075385
Drug: Disease management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease management program (single 1- to 1.5-hour education session, action plan for self-treatment of exacerbations, monthly follow-up calls)
Study: 18578170
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide solution (Opalescence)
Study: 18578170
Drug: 22% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22% carbamide peroxide solution (Nite White Excel 3)
Study: 16055224
Drug: Matrix-in-cylinder system
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix-in-cylinder system (80 mg propranolol hydrochloride)
Study: 16055224
Drug: Matrix-in-cylinder system
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix-in-cylinder system (80 mg propranolol hydrochloride) under fed conditions
Study: 16055224
Drug: Matrix-in-cylinder system
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix-in-cylinder system (80 mg propranolol hydrochloride) under fasted conditions
Study: 16055224
Drug: Inderal (commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderal (commercial pellet formulation)
Study: 10356104
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone or in combination with low doses of warfarin
Study: 10356104
Drug: Estrogen hormone
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen hormone replacement therapy among SPAF III participants
Study: 1954814
Drug: Usual insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual insulin (isoglycemic study)
Study: 1954814
Drug: Omitting morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omitting morning short‐acting insulin (hyperglycemic study)
Study: 27765365
Drug: Oligopin (OP)
Normalized name: OP-145
DrugBank: OP-145 (DB05672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligopin (OP) 75 mg, 2 capsules/day for 5 weeks
Study: 24997315
Drug: Prior unsuccessful
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior unsuccessful eradication treatments
Study: 16210486
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV), two doses in a 4- to 6-week interval, followed by a booster dose of 23-valent polysaccharide vaccine (PPV) after one year
Study: 16210486
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine (PPV), two doses in a 1-year interval
Study: 9868644
Drug: 400‐mg once‐weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400‐mg once‐weekly fluconazole
Study: 9868644
Drug: 200‐mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mg daily fluconazole
Study: 7993990
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg pyrantel pamoate tablet formulation
Study: 7993990
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg pyrantel pamoate suspension formulation
Study: 7993990
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg pyrantel pamoate other formulation
Study: 3197751
Drug: Oral ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketanserin 40 mg b.d. for two months
Study: 3197751
Drug: Oral ketanserin
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketanserin treatment
Study: 25563311
Drug: BUD plus
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD plus oral MONT (10 μg, qn) for 4 weeks
Study: 25563311
Drug: Inhaled BUD
Normalized name: Clove buds
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled BUD (200 μg, bid) for 4 weeks
Study: 20856190
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (specific dosage and duration not mentioned)
Study: 17976988
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m² orally bid days 1-14
Study: 17976988
Drug: Vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 30 mg/m² i.v. days 1 and 8
Study: 12510181
Drug: Electrical acupuncture
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical acupuncture therapy via adhesive surface electrodes and auricular acupuncture therapy
Study: 8944408
Drug: Chlorpromazine 100
Normalized name: chlorpromazine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine 100 mg
Study: 1629823
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous methotrexate (MTX) (500 mg/m2) followed by oral leucovorin every 2 weeks for up to 6 months
Study: 1629823
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose MTX after the high dose protocol
Study: 9793671
Drug: Cisatracurium, 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium, 0.20 mg.kg‐1 (4 x ED95)
Study: 9793671
Drug: Cisatracurium, 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium, 0.30 mg.kg‐1 (6 x ED95)
Study: 9793671
Drug: Vecuronium, 0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium, 0.30 mg.kg‐1 (6 x ED95)
Study: 9793671
Drug: Cisatracurium, 0.40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium, 0.40 mg.kg‐1 (8 x ED95)
Study: 336056
Drug: NAB 365
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NAB 365 (clenbuterol-HCl) 24 micrograms, 3 times daily for 7 days
Study: 336056
Drug: Fenoterol HBr
Normalized name: fenoterol hydrobromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol HBr 5 mg, 3 times daily for 7 days
Study: 27631775
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (SC) - 5×5 Gy in 1 week, early surgery, and 6 courses of adjuvant chemotherapy.
Study: 27631775
Drug: Long-course chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course chemoradiotherapy (LC) - 50.4 Gy in 28 fractions over 5.5 weeks with infusion of 5-fluorouracil, surgery in 4 to 6 weeks, and 4 courses of chemotherapy.
Study: 26437027
Drug: Magnetic sphincter
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic sphincter augmentation device (MSAD)
Study: 11437028
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 60 microg PGE1 over 2 hours during pedalergometry
Study: 9557427
Drug: Thiamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine (25 mg/day) and Pyridoxine (50 mg/day)
Study: 9557427
Drug: Thiamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine (1 mg/day) and Pyridoxine (1 mg/day)
Study: 8345047
Drug: Nal-Glu plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nal-Glu plus T (100 micrograms/kg.day sc plus T enanthate, 200 mg im weekly)
Study: 8345047
Drug: T alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: T alone (placebo sc injections daily plus T enanthate, 200 mg im weekly)
Study: 3725517
Drug: Monthly booster
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly booster sessions after training
Study: 27010809
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose before PPCI, followed by 90 mg twice daily for 1 year)
Study: 27010809
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose before PPCI, followed by 75 mg once daily for 1 year)
Study: 22732382
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium cream 4%
Study: 15922820
Drug: Nizatidine oral
Normalized name: nizatidine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine oral solution (2.5 mg/kg or 5 mg/kg BID)
Study: 15922820
Drug: Nizatidine extemporaneous
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine extemporaneous solution (2.5 mg/kg or 5 mg/kg BID)
Study: 15922820
Drug: Nizatidine capsules
Normalized name: Nizatidine Capsules
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine capsules (150 mg BID for ages 13-18)
Study: 15922820
Drug: Nizatidine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (all formulations)
Study: 12876092
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or plenary presentation
Study: 12876092
Drug: Pharmaceutical sponsorship
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical sponsorship
Study: 1442614
Drug: Low-dose dofetilide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dofetilide (3 micrograms/kg loading dose over 15 minutes and 1.5 micrograms/kg maintenance dose over 45 minutes)
Study: 1442614
Drug: High-dose dofetilide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dofetilide (6 + 3 micrograms/kg)
Study: 31680621
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon β‐1a
Study: 30727881
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg non-labeled ACT-541468 with 250 nCi of 14C-labeled ACT-541468
Study: 17130328
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg x kg(‐1)) before and after cardiopulmonary bypass
Study: 12480972
Drug: Subcutaneous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous erythropoietin (Epo) given every 1-3 weeks to maintain hemoglobin at 12.5 g% and intravenous iron (Fe) as necessary.
Study: 12480972
Drug: Subcutaneous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous erythropoietin (Epo) and intravenous iron (Fe) treatment.
Study: 1609038
Drug: Gepirone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone at a mean dose of 16.25 mg/day
Study: 3928422
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intraduodenal amino acid infusion
Study: 3928422
Drug: Intrajejunal amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrajejunal amino acid infusion
Study: 31915146
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physical activity and diet quality
Study: 31915146
Drug: Physical activity,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity, diet quality, and their combination
Study: 24071616
Drug: PVBs and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVBs and propofol-based total intravenous anesthesia
Study: 18621090
Drug: BioDis method
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioDis method for drug release prediction
Study: 18621090
Drug: Novel pH-
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel pH- and time-based multi-unit formulations
Study: 14594516
Drug: Sustained-release oral
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oral morphine (30 mg every 12 h, then titrated)
Study: 11329100
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of antibiotic therapy (2 days of cefuroxime 750 mg IV every 8 hours followed by 5 days of cefuroxime axetil 500 mg orally every 12 hours)
Study: 11329100
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of antibiotic therapy (2 days of cefuroxime 750 mg IV every 8 hours followed by 8 days of cefuroxime axetil 500 mg orally every 12 hours)
Study: 7772359
Drug: esmolol 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: esmolol 1.4 mg/kg
Study: 2127787
Drug: 1 million
Normalized name: Nystatin 1 MILLION U Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 million units of interferon alfa-2b, subcutaneously thrice weekly for 6 months
Study: 2127787
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of interferon alfa-2b, subcutaneously thrice weekly for 6 months
Study: 30388112
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered lyophilized fecal microbiota product (n = 31)
Study: 22344198
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 11.25 mg
Study: 22344198
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot 30 mg
Study: 20640511
Drug: Over-the-counter sales
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter sales of antibiotics
Study: 20640511
Drug: Injection antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection antibiotics
Study: 20640511
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of penicillins including β-lactamase inhibitors
Study: 17998490
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (50 mg, alternate days)
Study: 12243918
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of oral amoxicillin
Study: 12243918
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of oral amoxicillin
Study: 2188379
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg daily
Study: 31112641
Drug: Midazolam (M;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (M; 6 mg/kg IM)